Overview

A Study of Sotorasib in People With Brain Tumors

Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.
Phase:
PHASE1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Amgen
Treatments:
sotorasib